Regeneron Pharmaceuticals, Inc.

NASDAQ (USD): Regeneron Pharmaceuticals, Inc. (REGN)

Last Price

906.54

Today's Change

-0.78 (0.08%)

Day's Change

904.41 - 915.70

Trading Volume

344,627

Overview

Market Cap

97 Billion

Shares Outstanding

107 Million

Avg Volume

464,848

Avg Price (50 Days)

950.95

Avg Price (200 Days)

861.27

PE Ratio

26.10

EPS

34.73

Earnings Announcement

02-May-2024

Previous Close

907.32

Open

906.90

Day's Range

904.41 - 915.7

Year Range

684.81 - 998.33

Trading Volume

373,468

Price Change Highlight

1 Day Change

-0.09%

5 Day Change

-0.81%

1 Month Change

-6.28%

3 Month Change

-4.40%

6 Month Change

12.71%

Ytd Change

0.17%

1 Year Change

13.74%

3 Year Change

80.88%

5 Year Change

166.27%

10 Year Change

208.95%

Max Change

4191.31%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment